KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash from Financing Activities (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cash from Financing Activities data on record, last reported at -$780.1 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 31.3% year-over-year to -$780.1 million; the TTM value through Dec 2025 reached -$3.7 billion, down 68.84%, while the annual FY2025 figure was -$3.7 billion, 68.84% down from the prior year.
  • Cash from Financing Activities reached -$780.1 million in Q4 2025 per REGN's latest filing, down from -$717.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $64.7 million in Q1 2022 and bottomed at -$1.1 billion in Q4 2024.
  • Average Cash from Financing Activities over 5 years is -$534.2 million, with a median of -$478.1 million recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 117.66% in 2022, then crashed 2412.53% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$366.4 million in 2021, then surged by 32.42% to -$247.6 million in 2022, then tumbled by 80.17% to -$446.1 million in 2023, then plummeted by 154.54% to -$1.1 billion in 2024, then soared by 31.3% to -$780.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$780.1 million in Q4 2025, -$717.9 million in Q3 2025, and -$1.1 billion in Q2 2025.